Novavax, Inc. (NVAX): Interesting Series Of Developments Taking Place

Novavax, Inc. (NASDAQ:NVAX) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 326.65M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Novavax, Inc. (NASDAQ:NVAX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NVAX, the company currently has 105.98 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 355.71 million in total assets, balanced by 414.77 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Novavax, Inc. (NVAX) saw -13.64 million in free cash flow last quarter, representing a quarterly net change in cash of -1.71 million. Perhaps most importantly where cash movements are concerned, the company saw about -12.4 million in net operating cash flow.

Novavax, Inc. (NASDAQ:NVAX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 6.73 million in total revenues. That represents a quarterly year/year change in revenues of 1.68 in sequential terms, the NVAX saw sales decline by 0.18.

But what about the bottom line? After all, that’s what really matters in the end. Novavax, Inc. (NVAX) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 283.44 million, this means overall earnings per share of -0.16. Note, this compares with a consensus analyst forecast of -0.16 in earnings per share for its next fiscal quarterly report.

Is Novavax, Inc. (NASDAQ:NVAX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.53 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Novavax, Inc..

Previous ArticleNext Article

Related Post

Should You Buy Tractor Supply Company (TSCO) or KA... Tractor Supply Company (NASDAQ:TSCO) and KAR Auction Services, Inc. (NYSE:KAR) are the two most active stocks in the Specialty Retail, Other industry ...
Is Marriott International, Inc. (MAR) Investing It... Marriott International, Inc. (NASDAQ:MAR) fell by -0.31% in Monday’s trading session from $115.11 to $114.75 The stock price went upward in 7 of the l...
Helios and Matheson Analytics Inc. (HMNY) Key Indi... Helios and Matheson Analytics Inc. (NASDAQ:HMNY) gained 39.54% in Friday’s trading session, going up from its prior closing price of $2.63 to $3.67, a...
Does Alliqua BioMedical, Inc. (ALQA) Present Much ... Alliqua BioMedical, Inc. (NASDAQ:ALQA) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of...
DURECT Corporation (DRRX) Raising Eyebrows Among I... It is interesting to note that DURECT Corporation (NASDAQ:DRRX) is active and made a solid movement in the last trading day. Now trading with a market...